MRUS:NSD-Merus N.V. (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 53.94

Change

-0.30 (-0.55)%

Market Cap

USD 0.24B

Volume

0.62M

Analyst Target

USD 19.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Merus BV is a clinical stage immuno-oncology company. It is engaged in developing bispecific antibody therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing MRUS

GWX SPDR® S&P International .. 0.00 % 0.40 %

+0.87 (+0.31%)

N/A
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.12 (+0.31%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 96.15% 92% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 96.15% 92% A 96% N/A
Trailing 12 Months  
Capital Gain 100.52% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 100.52% 93% A 96% N/A
Trailing 5 Years  
Capital Gain 278.26% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 278.26% 92% A 93% A
Average Annual (5 Year Horizon)  
Capital Gain 29.98% 78% C+ 84% B
Dividend Return 29.98% 78% C+ 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.25% 51% F 30% F
Risk Adjusted Return 54.26% 95% A 82% B
Market Capitalization 0.24B 94% A 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 6.89 21% 17%
Price / Cash Flow Ratio -26.13 95% 90%
Price/Free Cash Flow Ratio -13.73 92% 87%
Management Effectiveness  
Return on Equity -52.79% 64% 31%
Return on Invested Capital -52.95% 55% 22%
Return on Assets -24.89% 64% 21%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector